The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Significance of the RADIANT-4 Study for Advanced Nonfunctional NETs of Lung or Gastrointestinal Origin

Jennifer Eads, MD
Published Online: 5:39 PM, Fri October 16, 2015

Jennifer Eads, MD, assistant professor of Medicine, senior clinical instructor of Medicine, Case Western University, reflects on the phase III RADIANT-4 study, which examined everolimus in advanced nonfunctional neuroendocrine tumors of lung or gastrointestinal origin.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.